严重多重用药增加老年炎症性肠病患者住院风险
该回顾性单中心研究纳入2011年9月1日至2022年12月31日的512例老年炎症性肠病患者,评估多重用药(≥5种药物)和潜在不适当用药(PIM)的患病率、预测因素及对1年住院率的影响。结果显示,初始就诊时74.0%存在多重用药,42.6%接受至少一种PIM;严重多重用药(≥10种药物)从初始28.6%增至末次38.6%(P<0.01)。严重多重用药(校正HR 1.95,95%CI 1.29-2.92)和PIM使用(校正HR 2.16,95%CI 1.37-3.43)均与1年内全因住院显著相关。
要点
- 老年IBD患者多重用药普遍,初始就诊时74.0%存在多重用药,42.6%使用至少一种PIM。
- 严重多重用药从初始28.6%增至末次38.6%(P<0.01)。
- 严重多重用药和PIM使用均与1年内全因住院风险增加独立相关。
核心结论
- 严重多重用药在超过25%的老年IBD患者中初始存在,并在初始就诊后4年内增至34%。
- 严重多重用药及多重用药者的PIM使用均与1年住院风险增加相关,凸显该人群需要减药干预。
研究设计与样本
- 回顾性单中心研究,纳入2011年9月1日至2022年12月31日的512例老年炎症性肠病患者。
- 采用Wilcoxon符号秩检验和McNemar检验评估就诊间多重用药变化,采用有序逻辑回归和Cox比例风险模型分别确定多重用药危险因素和住院时间。
主要发现
- 初始就诊时74.0%的患者存在多重用药(≥5种药物),42.6%接受至少一种PIM。
- 严重多重用药(≥10种药物)在初始就诊时占28.6%,末次就诊时增至38.6%(P<0.01)。
- 多因素分析显示,年龄≥70岁、体重指数≥30.0 kg/m²、既往IBD相关手术及存在合并症与多重用药相关。
- 严重多重用药与初始就诊后1年内全因住院显著相关(校正HR 1.95,95%CI 1.29-2.92)。
- 多重用药者中PIM使用与1年内全因住院显著相关(校正HR 2.16,95%CI 1.37-3.43)。
临床怎么用
- 原文结论指出,严重多重用药及多重用药者的PIM使用与1年住院风险增加相关,凸显该人群需要减药干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: As the inflammatory bowel disease (IBD) patient population is aging, the prevalence of polypharmacy is rising. However, data exploring the prevalence, risk factors, and clinical outcomes associated with polypharmacy among older adults with IBD are limited. The aim of the study is to determine (i) prevalence of polypharmacy (≥5 medications) and potentially inappropriate medication (PIM) utilization in older adults with IBD, (ii) changes in medications over time, (iii) predictors of polypharmacy, and (iv) the impact of polypharmacy/PIMs on 1-year hospitalization rates. METHODS: We conducted a retrospective single-center study of older adults with IBD from September 1, 2011, to December 31, 2022. Wilcoxon-signed rank and McNemar tests were used to assess changes in polypharmacy between visits, with ordinal logistic regression and Cox proportional hazards models used to determine risk factors for polypharmacy and time to hospitalization, respectively. RESULTS: Among 512 older adults with IBD, 74.0% experienced polypharmacy at the initial visit, with 42.6% receiving at least one PIM. In addition, severe polypharmacy (≥10 medications) was present among 28.6% individuals at the index visit and increased to 38.6% by the last visit ( P < 0.01). Multivariable analysis revealed that age ≥70 years, body mass index ≥30.0 kg/m 2 , previous IBD-related surgery, and the presence of comorbidities were associated with polypharmacy. Moreover, severe polypharmacy ( adj hazard ratio 1.95, 95% confidence interval 1.29-2.92), as well as PIM use ( adj hazard ratio 2.16, 95% confidence interval 1.37-3.43) among those with polypharmacy, was significantly associated with all-cause hospitalization within a year of the index visit. DISCUSSION: Severe polypharmacy was initially present in more than 25% of older adults with IBD and increased to 34% within 4 years of the index visit. Severe polypharmacy, as well as PIM utilization among those with polypharmacy, were also associated with an increased risk of hospitalization at 1 year, highlighting the need for deprescribing efforts in this population.
引用
- Drittel D, Schreiber-Stainthorp W, Delau O, et al. Severe Polypharmacy Increases Risk of Hospitalization Among Older Adults With Inflammatory Bowel Disease. Am J Gastroenterol. 2024. PMID: 39162710. doi:10.14309/ajg.0000000000003036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。